Lisa Beck, MD
Dermatology · Rochester, NYNPI 1780649681
Payments from drug & device makers
Across 734 payments — averaging $3144.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$618K
- Regeneron$396K
- Sanofi$311K
- AbbVie$210K
- Kiniksa Pharmaceuticals, Ltd.$191K
- LEO Pharma AS$149K
- plus $433K from 25 others
Across 240 payments — averaging $659.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$127K
- Pfizer$18K
- Sanofi$11K
- AbbVie$2K
What the payments were for
- Consulting fees$565,40075%
- Speaking & faculty fees$113,35615%
- Travel & lodging$69,3289%
- Food & beverage$6,5701%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 52 | $617,987 |
| Regeneron | 140 | $396,102 |
| Sanofi | 109 | $311,142 |
| AbbVie | 88 | $209,675 |
| Kiniksa Pharmaceuticals, Ltd. | 124 | $191,175 |
| LEO Pharma AS | 39 | $148,844 |
| Sanofi-aventis U.S. LLC | 21 | $83,644 |
| Astrazeneca UK Limited | 11 | $55,568 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $47,686 |
| Sanofi US Services Inc. | 9 | $36,705 |
| UCB, Inc. | 10 | $24,630 |
| UCB SA | 13 | $22,926 |
| Dermavant Sciences, Inc. | 12 | $17,683 |
| LEO Pharma Inc. | 5 | $17,210 |
| Regeneron Healthcare Solutions, Inc. | 18 | $16,891 |
| Novartis | 13 | $16,558 |
| Merck | 16 | $16,249 |
| Janssen Global Services, LLC | 3 | $15,100 |
| GSK | 4 | $13,897 |
| Amgen | 13 | $12,029 |
| Incyte Corporation | 8 | $10,330 |
| Mallinckrodt Hospital Products Inc. | 1 | $7,150 |
| Galderma Laboratories, L.p. | 6 | $5,575 |
| Janssen Research & Development, LLC | 3 | $5,200 |
| Arcutis Biotherapeutics, Inc. | 2 | $3,750 |
| Gilead | 1 | $1,660 |
| AstraZeneca | 4 | $1,471 |
| Almirall LLC | 1 | $525 |
| Genentech USA, Inc. | 2 | $231 |
| Blueprint Medicines Corporation | 1 | $104 |
| Eli Lilly | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,307,732 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 22 | $77,564 |
| Dupixent PenDupilumab | 19 | $64,692 |
| Ketoconazole | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Rochester
- John TuRochester$5.4M
- Anna DebenedettoRochester$749K
- Mary Gail MercurioRochester$655K
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- Jeffrey WeinbergKew Gardens$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.